Galapagos « Terug naar discussie overzicht

quote:

Toert schreef op 3 mei 2019 13:57:

[...]

Ik dacht 113.47 omgekeerd, dat is dan 7 4 komma 3 1 1

quote:

Fat Clemenza schreef op 3 mei 2019 15:31:

Zoals voorspeld kan het zo nog weken aanmodderen rond de 100€ .
Maar als definitief blijkt dat er geen goedkeuring komt voor fignotehypehype in de US en belangrijker het een matig me too product is met safety issues, kan de duikvlucht beginnen.

quote:

egeltjemetstekel schreef op 3 mei 2019 15:24:

seekingalpha.com/article/4259526?sour...

quote:

egeltjemetstekel schreef op 3 mei 2019 15:24:

seekingalpha.com/article/4259526?sour...

Quote:

"Getting filgotinib in gear
O'Day waxed rhapsodic about this JAK inhibitor, which has completed three Phase 3 studies for rheumatoid arthritis, with other autoimmune disease indications being studied. He is not taking the male fertility issue - a question raised by an animal study or studies - lying down. He is insisting that an EU filing be done ASAP, i.e. in H2 this year. As far as the FDA, the company will meet with the FDA ASAP as well to discuss next steps. I would expect that the CEO will want to be present for this meeting. GILD will argue that filgotinib may be best in its class, and that most cases of RA are in women; and that in men, many are beyond child-bearing age anyway. O'Day made it clear that time is of the essence in launching this important product for RA."

quote:

Baquerizo Moreno. schreef op 3 mei 2019 15:36:

SVP houd u allen in en reageer niet op bericht van fc hierboven

quote:

Sentiment schreef op 3 mei 2019 15:35:

[...]Dat doet pijn hè? Short zitten bij Gala

quote:

Fat Clemenza schreef op 3 mei 2019 15:31:

Zoals voorspeld kan het zo nog weken aanmodderen rond de 100€ .
Maar als definitief blijkt dat er geen goedkeuring komt voor fignotehypehype in de US en belangrijker, het een matig me too product is met safety issues, kan de duikvlucht beginnen.

quote:

Fat Clemenza schreef op 3 mei 2019 15:50:

[...]

Dat niet maar kost veel tijd (ingecalculeerd) door alle hype en fake news rondom.

quote:

egeltjemetstekel schreef op 3 mei 2019 16:12:

finance.yahoo.com/news/gilead-science...

Quote:

"Has the tide turned?
Gilead's prospects as a growth stock have dramatically improved lately. Beyond Yescarta's positive sales momentum and Biktarvy's rapid adoption, the company recently announced positive late-stage results for filgotinib as a treatment for rheumatoid arthritis. This experimental anti-inflammatory medicine, licensed from Galapagos N.V., should start to become a major part of the company's core value proposition in 2021. The biotech also has a surfeit of cash to pursue late-stage clinical candidates or newly launched products"

quote:

egeltjemetstekel schreef op 3 mei 2019 16:12:

finance.yahoo.com/news/gilead-science...

Quote:

"Has the tide turned?
Gilead's prospects as a growth stock have dramatically improved lately. Beyond Yescarta's positive sales momentum and Biktarvy's rapid adoption, the company recently announced positive late-stage results for filgotinib as a treatment for rheumatoid arthritis. This experimental anti-inflammatory medicine, licensed from Galapagos N.V., should start to become a major part of the company's core value proposition in 2021. The biotech also has a surfeit of cash to pursue late-stage clinical candidates or newly launched products"

quote:

egeltjemetstekel schreef op 3 mei 2019 15:24:

seekingalpha.com/article/4259526?sour...

Quote:

"Getting filgotinib in gear
O'Day waxed rhapsodic about this JAK inhibitor, which has completed three Phase 3 studies for rheumatoid arthritis, with other autoimmune disease indications being studied. He is not taking the male fertility issue - a question raised by an animal study or studies - lying down. He is insisting that an EU filing be done ASAP, i.e. in H2 this year. As far as the FDA, the company will meet with the FDA ASAP as well to discuss next steps. I would expect that the CEO will want to be present for this meeting. GILD will argue that filgotinib may be best in its class, and that most cases of RA are in women; and that in men, many are beyond child-bearing age anyway. O'Day made it clear that time is of the essence in launching this important product for RA."